Unicycive announces puvlication of OLC positive bioequivalence data

Unicycive Therapeutics (UNCY) announced that data from the Company’s oxylanthanum carbonate, OLC, bioequivalence study in healthy volunteers was published in the peer-reviewed journal, Clinical Therapeutics. The publication, entitled, “Two-Way Randomized Crossover Study to Establish Pharmacodynamic Bioequivalence Between Oxylanthanum Carbonate and Lanthanum Carbonate” described the study that established pharmacodynamic bioequivalence of OLC to Fosrenol. In the study, OLC was well tolerated and demonstrated bioequivalence to lanthanum carbonate.